How Successful Is Stem Cell Therapy for Shoulders?

Stem cell therapy for shoulders shows genuine promise in some contexts and disappointing results in others, and the gap between marketing claims and clinical evidence remains wide. When used alongside surgical rotator cuff repair, stem cells appear to improve structural healing on imaging, though the benefit in terms of what patients actually feel is less clear. As a standalone injection without surgery, the picture is murkier: at least one sham-controlled trial found that a saline injection performed just as well as a stem cell injection for tendon tears. The honest answer depends heavily on which shoulder condition you have, what type of cells are used, and whether surgery is part of the plan.

Stem Cells as an Add-On to Rotator Cuff Surgery

The strongest evidence for stem cell therapy in shoulders comes from studies where cells are applied during a surgical rotator cuff repair, not as a replacement for surgery. The idea is straightforward: the surgeon fixes the torn tendon, then adds a concentrate of stem cells to the repair site to help it heal more completely. Several studies suggest this approach improves what the tendon looks like on imaging afterward.

In a prospective randomized trial, patients who received bone marrow concentrate during arthroscopic rotator cuff repair had a retear rate of 18% on MRI at one year, compared with 57% in patients who had surgery alone. That is a striking structural difference. But here is the catch: treatment failure rates were nearly identical between the two groups, at about 15-16%, and patient-reported outcomes were not significantly better with the stem cell augmentation.¹ In other words, the repaired tendons looked better on scans, but patients did not feel meaningfully different.

A separate case-controlled study found more dramatic results: all 45 repairs augmented with bone marrow-derived mesenchymal stem cells had healed by six months, compared with only 67% of the 45 repairs without stem cell treatment.² A systematic review looking across available studies concluded that bone marrow aspirate concentrate has not been linked to increased complication rates, and some evidence suggests it may enhance healing, pain relief, and function, though the studies vary widely in design and methods.³

One practical question surgeons have explored is whether adding platelet-rich plasma on top of bone marrow concentrate makes a difference. A meta-analysis found that the functional outcomes were essentially the same whether patients received bone marrow concentrate alone or bone marrow concentrate combined with PRP, which suggests the simpler, cheaper approach may be just as effective.⁴

Standalone Injections Without Surgery

Many people considering stem cell therapy for their shoulders are hoping to avoid surgery entirely. Clinics market injections of stem cells or stem cell concentrates as a way to heal torn tendons or reduce chronic pain without going under the knife. The evidence here is far more conflicted than the marketing suggests.

A study of patients with partial rotator cuff tears compared bone marrow concentrate plus PRP injections against a control group. At three months, the injection group had better pain and function scores. But the tear itself did not significantly shrink in either group.⁵ A related study tracking the same type of injection found that while pain dropped from about 5.8 to 2.8 on a 10-point scale over three months, the torn tendon area shrank from roughly 30 to 23 square millimeters, a reduction that was not statistically significant.⁶ Patients felt better, but the structural damage remained largely unchanged.

The most sobering data comes from a randomized controlled trial that included a saline placebo group, something most stem cell studies lack. Patients with tendon tears received either a stem cell injection, an active control injection, or plain saline. At three months, there were no significant differences between groups in pain scores or shoulder function scores. If anything, the saline group improved the most.⁷ This is a critical finding because it suggests that at least some of the improvement patients report after stem cell injections could be a placebo effect, or simply the natural course of healing combined with the attention and rehab that comes with any treatment.

Not every head-to-head comparison is so discouraging. A study comparing adipose-derived regenerative cells against corticosteroid injections for partial-thickness rotator cuff tears found that the stem cell group had significantly better pain and function scores at six months, one year, and even at an average of about 40 months after treatment.⁸ That comparison is worth noting because corticosteroids are the standard injection for shoulder pain, and they tend to lose effectiveness within weeks. Beating corticosteroids, though, is a different bar than beating placebo.

Shoulder Osteoarthritis

Rotator cuff tears get most of the attention, but shoulder osteoarthritis is another condition where stem cell injections are being tried. The glenohumeral joint wears down with age just like the knee, and for patients who are not ready for a shoulder replacement, the treatment options are limited.

A study that followed patients for three years after injections of micro-fragmented adipose tissue into arthritic shoulders found that about 83% of patients were completely satisfied with the treatment at the 36-month mark, with sustained improvements in shoulder scores and pain.⁹ A pilot study using a combination of bone marrow aspirate, lipoaspirate, and PRP for glenohumeral osteoarthritis also found large improvements in pain and function, though as a small pilot it can only be considered preliminary.¹⁰

A review in JBJS Reviews noted that while orthobiologic therapies including cell-based treatments show promise for glenohumeral osteoarthritis, more definitive studies are still needed.¹¹ The general pattern with osteoarthritis mirrors what we see with rotator cuff tears: patients tend to report feeling better, and the improvements can last a few years, but none of these studies include sham controls, so it is impossible to say how much of the benefit is truly from the cells versus the injection procedure itself or natural fluctuation in symptoms.

When Structural Healing Actually Happens

One of the more intriguing findings in this space is that higher doses of stem cells seem to produce real, visible changes in tendon structure. In a first-in-human trial using adipose-derived mesenchymal stem cells injected directly into partial-thickness rotator cuff tears, MRI showed that the volume of the tendon defect decreased by roughly 90% in the high-dose group, and arthroscopic examination confirmed similar reductions. Pain disability scores dropped by about 77-80%, and shoulder pain fell by about 71% in the high-dose group.¹²

A two-year follow-up of the same patient group found that the tendon defects in the high-dose group had nearly disappeared by one year and did not return at two years. Supraspinatus strength increased by more than 50%, and shoulder function scores continued to improve across all dose groups through the two-year window.¹³ These are encouraging numbers, but the study had no control group receiving a sham injection, so the door stays open for questions about what is driving the improvement.

This disconnect between structural findings and patient-reported outcomes keeps appearing. In the surgical augmentation trial mentioned earlier, MRI looked better with stem cells but patients felt about the same. In standalone injection studies, patients felt better but tears did not reliably shrink. The high-dose adipose study is one of the few where both structure and symptoms seemed to improve together, but it lacked the sham control that would make the findings definitive. The field is, frankly, still figuring out the relationship between what happens inside the tendon and what the patient experiences.

Long-Term Durability

Most stem cell therapy studies in the shoulder track patients for one to three years. Longer data is scarce but exists for certain conditions. A prospective randomized study of patients with early post-traumatic shoulder osteonecrosis, a condition where bone dies after injury, followed patients for an average of 12 years. In the stem cell therapy group, 92% of patients avoided needing a shoulder replacement, compared with just 25% in the control group. Bone collapse, the hallmark of progressing osteonecrosis, occurred in about 12% of the cell therapy group versus nearly 88% of controls.¹⁴

This is an unusually strong result, but it applies to a very specific condition, osteonecrosis rather than typical rotator cuff disease or osteoarthritis. Still, it demonstrates that mesenchymal stem cells can produce durable structural changes in the shoulder when the biological context is right. Whether those kinds of long-term benefits translate to more common shoulder problems like chronic tendon tears remains an open question.

How the Cells Actually Work in the Shoulder

The prevailing theory is that stem cells do not primarily work by turning into new tendon tissue. Instead, they act more like biological pharmacies, secreting molecules that calm inflammation and encourage the body’s own repair processes. Research has shown that stem cell-derived particles can increase collagen production, shift the local immune response away from inflammation and toward healing, and reduce levels of destructive enzymes at the injury site.¹⁵ Lab studies have also shown that when combined with glucocorticoids, stem cell-derived particles produce a stronger anti-inflammatory effect than either alone.¹⁶

This paracrine mechanism, where the cells help by what they release rather than what they become, has implications for how we think about dosing and delivery. If the cells are working through signaling molecules, then getting enough cells to the right spot matters a great deal, which may explain why higher-dose injections seem to produce better outcomes in some trials.

Safety Profile

On the safety side, the news is reassuring. A first-in-human pilot study of adipose-derived cell injections for partial-thickness rotator cuff tears found no severe adverse events related to the treatment over 12 months. The risks were no greater than those associated with a standard corticosteroid injection. In fact, one patient in the corticosteroid group progressed to a full-thickness rotator cuff tear during the study period, while no such progression occurred in the stem cell group.¹⁷ This aligns with the broader systematic review finding that bone marrow concentrate has not been associated with increased complications in rotator cuff repair.³

The safety conversation gets more complicated when you consider what clinics are actually injecting. Autologous products, made from your own bone marrow or fat, have a cleaner safety record than allogeneic products from donor tissue. Animal research on umbilical cord blood-derived stem cells for rotator cuff tears has shown no adverse effects and significant tear-size reduction in a rabbit model,¹⁸ and reviews suggest these allogeneic approaches are safe and potentially effective, though human data from large randomized trials is still lacking.¹⁹

Cost and Regulatory Reality

Stem cell injections for shoulders are almost never covered by insurance. A prospective cohort study found the mean cost was about $6,000, with a range from $1,200 to $13,000, and the authors described the treatment as “costly and speculative.”²⁰ That is a significant out-of-pocket expense for a therapy that, as the sham-controlled trial demonstrated, may not outperform a saline injection in some settings.

The regulatory landscape in the United States adds another layer of complexity. The FDA regulates stem cell products through its human cells and tissues framework, and the extent to which cells are manipulated determines what a physician can legally do without explicit FDA approval.²¹ In 2021, the FDA ended a period of enforcement discretion for many biologic products, meaning that some treatments previously tolerated in clinics now technically require an investigational new drug application and a biologics license to be marketed legally.²²

What this means practically is that many clinics offering “stem cell therapy” for shoulders are operating in a gray zone. Products like bone marrow aspirate concentrate, where cells are harvested and minimally processed during a single procedure, generally fall under an exception that allows their use without FDA pre-approval. But products that involve culturing cells, combining them with other substances, or using donor-derived tissue face stricter scrutiny. If a clinic is advertising a treatment that sounds too specific or too polished, it is worth asking whether it has actually been through an FDA-sanctioned pathway.

How Stem Cell Therapy Compares to Standard Treatments

Regenerative treatments like PRP and adipose-derived stem cells tend to produce comparable or slightly better sustained outcomes in pain control and function relative to standard treatments for chronic rotator cuff tendinopathy. Corticosteroids work faster but fade within weeks, while PRP and stem cell treatments show more durable effects at 6 to 12 months and beyond.²³ But the magnitude of benefit is frequently modest and does not always reach thresholds that clinicians consider meaningful. And comparing stem cells directly to PRP is difficult because studies use different preparation methods, doses, and protocols, making apples-to-apples comparisons unreliable.²⁴

For someone weighing their options, the practical takeaway is that stem cell therapy is not a clear upgrade over PRP for most shoulder conditions. PRP is cheaper, more widely available, and has a broader evidence base. The cases where stem cells might add something are in surgical augmentation of large or complex tears, where the structural healing benefit has been more consistently demonstrated, and possibly in conditions like osteonecrosis where the biological mechanism is a particularly good match.

Scaffolds and Next-Generation Approaches

The next wave of research is not just about putting cells into the shoulder but about creating an environment where they work better. Injectable hydrogel scaffolds loaded with biological signals can recruit the body’s own stem cells to an injury site and guide them toward forming tendon-like tissue. One laboratory approach uses a composite of bioactive glass and a polymer membrane that releases different growth factors in sequence: first to calm inflammation and attract stem cells, then to drive them toward cartilage and tendon formation.²⁵ In animal models, an injectable chitosan hydrogel seeded with tendon-derived stem cells promoted orderly collagen formation and cartilage growth at the tendon-bone junction, exactly the interface that is hardest to heal in rotator cuff repairs.²⁶

These scaffold-based strategies are still in preclinical stages, but they address a real limitation of current stem cell injections: cells delivered as a liquid suspension often disperse quickly and do not stay where they are needed. If researchers can solve the delivery problem, stem cell therapy for shoulders could become substantially more effective. For now, though, these approaches are years away from clinical use, and the treatments available today remain a mix of modest benefit, significant cost, and genuine uncertainty about how much of the improvement stems from the cells themselves.